Greetings, and welcome to the IDEX Corporation First Quarter 2024 Earnings Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce Wendy Palacios, Vice President, FP&A and Investor Relations. Thank you. You may begin.

Good morning, everyone. This is Wendy Palacios, Vice President of FP&A and Investor Relations for IDEX Corporation. Thank you for joining us for our discussion of the IDEX First Quarter 2024 Financial Highlights. Last night, we issued a press release outlining our company's financial operating performance for the 3 months ending March 31, 2024. The press release, along with the presentation slides to be used during today's webcast, can be accessed on our company's website at www.idexcorp.com. Joining me today are Eric Ashleman, our Chief Executive Officer and President; and Abhi Khandelwal, our Senior Vice President and Chief Financial Officer. Before we begin, a brief reminder. This call may contain certain forward-looking statements that are subject to the safe harbor language in last night's press release and in IDEX filings with the Securities and Exchange Commission. With that, I'll turn this call over to our CEO and President, Eric Ashleman.

Thanks, Wendy, and good morning, everyone. In Q1, our core execution capabilities delivered strong results, particularly within our Fluid & Metering Technologies and Fire & Safety/Diversified Products businesses. We experienced an encouraging lift in sequential orders from our core industrial and municipal markets after a period of elongated destocking, and we were able to quickly capitalize on this bounce and deliver for our customers. Our lead times and overall responsiveness are at outstanding levels as we stripped out excess inventory and improved overall productivity. Our closest to consumption businesses within FMT pulled back a bit in March after a strong January and February launch, but things stabilized again in early April, suggesting our initial outlook for overall modest report for 2024 remains the correct call. The Health & Science Technologies segment performed as expected, but there are fluctuations as we consider individual recovery rates within our markets and application sets. Our tactical priorities favor those growth initiatives that best leverage our most differentiated technologies aligned with markets showing higher probabilities of near-term inflection. Largely through inorganic efforts, we've expanded our technical capabilities within HST to support the Highest Quality Semiconductor technologies to power the AI revolution. We have increased content within the transformative world of low orbit space broadband, and we are increasingly being called upon to help companies develop and deploy advanced technologies for national defense. We aim to continue adding to these capabilities as we leverage our balance sheet through M&A. We are monitoring signs of recovery in life sciences and analytical instrumentation, and we are ready to capitalize on growth at the first signs of improving customer demand. Our businesses serving these spaces are exceptionally well positioned with highly credible expertise. We have confidence in our ability to outperform again once this market correction runs its course. Overall, it's clear that economic and geopolitical uncertainty persists as a backdrop for all companies. We've leaned into that with conviction that the three core tenets of the IDEX difference—an expression of our most basic differentiated mindset—help us play offense. Our great teams and talent work together in superior businesses with a special culture. We practice 80-20 to align around the few things that really matter, and we leverage our natural proximity to the customer to solve their toughest problems quickly to support our outstanding economics. We ultimately create compounding value for shareholders by driving organic growth outperformance through our top growth bets. We amplify these bets through acquisition of complementary, faster-growing companies, and we expand margins and generate strong free cash along the way as our leaders apply the five core tools of the IDEX operating model. I'd like to thank our IDEX teams around the globe for their dedication to these principles and for delivering strong performance in Q1. With that, I'll turn it over to Abhi to discuss our financial results.

Thanks, Eric. Before jumping into the consolidated results, I want to highlight our team's consistent ability to execute, as you've seen in the results, delivering strong profitability and free cash flow in the first quarter despite challenging year-over-year comparables. Moving on to the consolidated financial results. All comparisons are against the prior year period unless stated otherwise. Quarters of $820 million in the first quarter were down both 1% overall organically. We experienced an organic decrease in FMT and HST, while FSDP grew low double digits, driven by strength in dispensing and emerging markets. First quarter sales of $801 million were down 5% overall and down 6% organically. We experienced a 13% organic decrease in HST and a 3% organic decrease in FMT, while FSDP grew by 2% organically. First quarter gross margin was 44.6%, declining 60 basis points, while adjusted gross margin was 45%, contracting 20 basis points due to volume leverage, partially offset by price/cost and operational productivity. First quarter adjusted EBITDA margin was 26%, down 120 basis points. This is a sequential improvement versus the fourth quarter of 20 basis points as we remain focused on margin expansion. I will discuss the drivers of first quarter adjusted EBITDA on the next slide. On a GAAP basis, our Q1 effective tax rate of 21.5% versus last year's first quarter effective tax of 22.2% decreased primarily due to a favorable discrete item. First quarter net income was $121 million, generating EPS of $1.60. Adjusted net income was $143 million with adjusted EPS of $1.88, down $0.21 from the prior year first quarter. Finally, free cash flow for the quarter was $137 million, up 13% over the prior year period. We achieved a conversion rate of 95% of adjusted net income, mainly driven by lower variable compensation payments and capital expenditures despite lower adjusted net income. On an organic basis, we drove more than $78 million of inventory reduction over the last 12 months, and we saw inventory turns improve by 0.4 turns year-over-year. Moving on to Slide 5, which details the driver of our first quarter adjusted EBITDA. For the first quarter, adjusted EBITDA decreased by $22 million compared to the first quarter of 2023. Our 6% organic sales reduction unfavorably impacted adjusted EBITDA by $29 million flowing through at our prior year adjusted gross margin rate. Price/cost was accretive to margins and we drove operational productivity that offset employee-related inflation. These results yielded a negative 50% organic flow-through. The impact of FX and acquisitions net of divestitures contributed $3 million of adjusted EBITDA in the quarter, resulting in a negative 48% flow-through. With that, I'll provide a deeper look at our segment performance. I'm on Slide 6, within our FMT segment. In our water businesses, municipal project activity remains strong. Note that water sales performance in the first quarter of the prior year was favorably impacted by both hurricane-related backlog execution and the catch-up of a 1-month lag treatment of the Nexsight acquisition, effectively recording 4 months of Nexsight sales in the first quarter of 2023. Our energy businesses remained stable, with favorable infrastructure tailwinds offset by a mild winter. Our agricultural businesses continue to be cyclically down, in line with expectations. Finally, Q1 adjusted EBITDA margins expanded 60 basis points, driven by price/cost and operational productivity despite slightly lower volumes. Moving on to Slide 7. Despite challenging year-over-year comparables, the Health & Science Technologies segment performed to expectations, and nearly all of our HST business saw sequential order improvement compared to the fourth quarter. Our teams continued focusing on our most strategic customers' next-gen solutions in life sciences and analytical instrumentation while we watch for signs of recovery. Our space, broadband, and laser communication initiatives continue to be on track despite current quarter customer delays. Our material processing technology business saw strength in food and sports nutrition that offset conservative customer capital investments within biopharma and pharma. For semiconductor, we saw orders improvement, both year-over-year and compared to the fourth quarter. And we expect these trends to continue in line with an improved outlook for memory chips. In line with our FMT industrial businesses, the HST industrials are steady. Lastly, adjusted EBITDA margins improved 40 basis points over the fourth quarter of last year. A year-over-year decline of 250 basis points was driven by volume leverage, partially offset by price/cost and operational productivity. Now turning to Slide 8. Our Fire & Safety/Diversified Products segment performance was driven by dispensing project wins in emerging markets, which helped offset the impact of key U.S. customers' multiyear refreshment cycle. We continue to see stability in Fire & Safety. In the quarter, our focus on strategic share gain initiatives helped partially offset unfavorable budget reallocations in the industry. BAND-IT automotive demand is strong, with growth expected in the year. Additionally, industrial performance was similar to FMT and HST with sequential improvement compared to Q4. Finally, adjusted EBITDA margins expanded 40 basis points, driven by price/cost. With that, I'd like to provide an update on our outlook for the second quarter. In Q2, we're projecting GAAP EPS to range from $1.75 to $1.80 and adjusted EPS to range from $2 to $2.05, with organic revenue decline of approximately 2% to 3% and adjusted EBITDA margin of approximately 27.5%. Turning to the full year 2024. We are maintaining our previously issued full-year outlook of organic revenue growth of 0% to 2% and adjusted EBITDA margin of approximately 28% and adjusted EPS of $8.15 to $8.45, with the majority of markets performing in line with our initial guidance and our focused efforts on driving growth bets.

Thanks, Abhi. I'd like to close by coming back to the simple value equation I talked about in my opening remarks. It all starts with organic growth outperformance, typically targeting 300 basis points above market entitlements. We drive about 20 to 25 basis points across the company at any one time to achieve these results. I highlighted earlier some examples of growth initiatives through Applied Technologies within HST. Within FMT, we're also integrating the recently acquired assets within our Intelligent Water group alongside our legacy technologies to support critical analytical work within municipal and industrial wastewater containment and processing. Also within FMT, we're deploying digital tools across multiple brands that go to market through distribution to enhance our customer experience and promote share gain. I'll go deeper in the quarters ahead with additional specific examples to help bring this work to life. We amplify these bets with complementary inorganic work via M&A to add another 200 to 300 basis points of growth. We see an outstanding opportunity to support faster-growing transformational markets through the disciplined build of relative and absolute scale within very high-quality niches. Over the last 3 years, we've been working this play in the intelligent water space within thin-film optics and within the niche of small form factor materials-intensive processing. Finally, we expand margins and seek to drive double-digit earnings growth along the way as our teams deploy the five basic IDEX operating model tools with 80-20 as our heartbeat. Our decentralized environment and collaborative culture supports speed and agility, and our inclination to resist top-heavy infrastructure supports financial leverage as we grow. In closing, the world is transforming and evolving in exciting, but unpredictable ways. We're building a company that can thrive and win in that environment where power meets speed and agility at the intersection of technology and culture. I look forward to communicating our progress with you along the way. With that, I'll turn it over to the operator for your questions.

Our first question comes from the line of Mike Halloran with Robert W. Baird.

So just a simple question, Eric. Maybe just talk about, in your mind, if anything has really changed in the market since you gave the last guidance or from an expectation perspective. Obviously, dispensing a little better in the first quarter, doesn't seem like your expectations for the remainder of the year are all that different. But when you go through some of the key end markets, has much really changed from an outlook perspective? And how are you thinking about the sequentials through the year versus normal seasonality, ignoring some of the positive things that you were driving with some of your investments?

Yes. No, thanks for the question. I mean not a lot that's different. I mean, I provided some color around the cadence of those smaller flow FMT order businesses that we have that are such good diagnostics. I think just to show that at the end of the day, the call remains the same, but it was interesting to watch the sensitivity and kind of ebb and flow in a way. It's a little unusual. Hot January and February, a little bit of pullback in March kind of coming back to equilibrium in April. So I think that's interesting mainly because I think it's reflective of the, frankly, the level of sensitivity that is out there as people track inflation, interest rates, and the election, but I think we still land at the same place. When we look at particularly the markets in HST, of course, about half of it is pretty industrial too, so it kind of follows the same rhythm and cadence. I think what we see is shoots of growth around the periphery of the larger pieces of HST. So our MPT business has some great things going on in terms of food production and our battery material handling, but not necessarily in the core pharma. That's still to come. We saw a little lift in ceiling around some consignment orders and largely in that memory chip world, but we still await the broader lift on the highest quality semiconductor offerings that we have in the company. So when you step back, I think broad but modest support on much of the industrial landscape of IDEX, and then I think a lot of attention for us back on those two core higher-growth potential markets within HST, life science and analytical instrumentation in the semiconductor markets, and kind of great '25 sitting there. It's just a question of how much in the back half do you start to see some velocity towards it. And that's pretty close to where we were, I think, 3 months ago.

Yes. No, makes sense. And then an HST margin question. Obviously, you're running well below peak right now. When you get mix-normalized and those end markets come back, whether it's '25 or later, back part of this year, as you just mentioned, how do you think about margin normalization? Is that 25% to 27% kind of range you're at towards peak, is that still the bogey for where you think things will be when you get a little more normalization? And maybe just put a little context around that because we're having some moving pieces to that segment.

Yes, Mike, this is Abhi. So I think if you go back 90 days and think about the discussion near the end of Q4, I think, look, what we've said is that the volumes come back in HST, more specifically in life sciences and the semicon that Eric just talked about. This business levers really well. And what we have said is we expect margins to be closer to 30% in HST once our volumes are back.

So 30% EBITDA margins when everything comes back, okay? Because the 25% to 27% just for clarity was me just previous margin ranges. So okay, that makes sense. We appreciate everyone.

Our next question comes from the line of Deane Dray with RBC Capital Markets.

Eric, I think you've given some of the color here, but just regarding your read on how the year is beginning to play out. Can you also touch on day rates and it sounded like BAND-IT started off well, so that's always a good sign. And anything else about the bellwethers, Warren Rupp and some of the others?

Yes. And that cadence that I articulated in the opening in Mike's question was really right there. It was on those bellwether businesses that we aggregate, take a look at weekly and then kind of use as an ultimate barometer of industrial health for IDEX. And I think, again, we saw those launching really strong in January, continued into February. It was interesting, a little bit of a pullback in March, and we had Easter earlier than ever before. So probably some of it. But to kind of see that swing and see it as broadly too certainly caught our attention; and yet then it stabilized again in April. So it's moving a little faster, both directions, than it typically has, and yet the arrow still remains kind of at the exact same slope that we thought. I just want to point it out because, again, I think it's reflective of some of the dialogue and conversations we're having, and this is higher up the food chain around projects, confidence, and where we are. It does seem more sensitive than I've seen in a long time to kind of whatever's on the news and what's out there, which isn't really surprising given kind of what this year is and where we are. So largely an unchanged position, but I thought the color might be helpful.

And just to build on it, I think the other thing it points to that we've had a lot of conversations around is normalization of the supply chain. So it's a lot faster when it turns on, a lot faster when it turns on because people know that the lead times are back to normal levels that they can adjust their demand as they see the markets move up and down.

That's real helpful. And I'm glad you mentioned about that normalization of the supply chain because that's been a focus. And just a separate question on the life sciences, analytical instruments market. We've been watching this and just kind of waiting where and how that—the destocking might run its course and it just really hasn't turned the corner yet. I did see one of the life science guys report a strong quarter, but that was more on the bioprocessing side, less on the instrument side. But what's the typical lag between what you see from the OEs in terms of their sales of instruments versus your supply of these components? I mean, I guess, some of it has to do with what their inventory levels are and whether they're running off their current stock and then whether they're pulling from—to you for their orders. But just the typical lag and any color there would be helpful.

Yes. So I think there's a couple of points to hit there. I'll start with the first where you ended. I mean the lag is—not extended for us because most of our replenished cycles and lead time fulfillment abilities and capabilities of components going to companies like that is really fast. I mean it's one of the reasons that when this sort of destocking cycle started, we were one of the first to recognize it back in Q4 of '22. And so I think any sign of life, we're going to see that first and it's—and we're going to see it probably pretty close to the time that they're talking about selling the instruments just because of the natural way that forecast would roll in and come back into our factories. We—typically, this is for most cases, I mean, we're not requiring months and quarters of heads-up on that just because we're set up to quick turn most of the components. I think maybe the only exception would be, look, if there's a material shift in the overall demand profile, then we've got to think about making sure that we get those same broader signals out to our suppliers and they do that with us. You have to have that conversation, but sort of the early turn in inflection would be relatively quickly aligned. The only other point kind of embedded in the earlier part of your question to come back to is just as we're all reading signals from the broader market, as you're thinking of IDEX, it's always important to recognize, we participate in the instrument side of those sales. And often, you'll see people are talking about consumable streams. And maybe those would tend to advance and start to move ahead of instruments. And so it's an interesting point, but you always have to kind of equate it back to and what's the velocity on instruments because ultimately, that's where the components that we supply go.

Our next question comes from the line of Vlad Bystricky with Citigroup.

I guess can you just talk about, and sorry if I missed it, what price versus cost overall actually was in the quarter and your expectations for price versus cost for the year and what you're seeing in terms of inflationary pressures versus your expectations coming into the year?

Yes, Vlad. This is Abhi and I'm more than happy to answer that for you. So if you recall, when we talked about our Q4 earnings, what we talked about was price for 2024, we'd laid it out at about 2%. But more importantly, what we were focused on was this price/cost spread of 80 to 100 basis points. So as you think about where we exited Q1, we were closer to that 100 basis points from a price/cost standpoint, in line with expectations, in fact, on the high end of expectations. If you go back in time and just look at IDEX historically, we've seen from a pricing standpoint something in the neighborhood of 80 to 1.2%—or 0.8% to 1.2%. So this pricing that we have laid out for '24 is higher than normal levels. And then the price/cost spread typically, what we've seen historically is 30 to 40 basis points versus what we're seeing here, which is 80 to 100 basis points. To answer your second question on inflation, what we're seeing is the input cost slightly favorable compared to what we had assumed in the guide that we had laid out as part of the Q4 discussion.

Great. That's helpful color. I appreciate it. And then just to go back to HST. In terms of the organic sales decline that we've seen in the quarter, are you able to give us more color on the underlying growth rates in industrial and semicon versus what you're seeing in life sciences and analytical instrumentation?

Well, a couple of things there. I mean, the comparisons in a lot of HST are at pretty exaggerated levels given the rapid destocking that we saw last year. And so let's— we've been talking about life science and analytical instrumentation as being in a general condition of kind of flat waiting for signs of recovery. And that, just from a segment percentage, is just over one-third of the entire segment. I think semicon certainly has high single-digit growth potential, and we're starting to see some early signs. I mentioned some things in ceiling and a couple of other places, but really have a little bit more of that dialed in, in the back half as we start to approach that entitlement. It's probably '25 though, before it really comes in at that full level. In the industrial space, we kind of talked about, it tracks with generally what we're saying about FMT and much of FSDP overall. So it's more modest in the low single-digit range right now. And I don't know, Abhi, do you want to add something there?

Yes. No, the only thing I'd add is I think just—look, we've talked about this, I think comparing it year-over-year is kind of tricky given what we saw last year. So I think it's important to kind of point out, if I look at the sequential order trends, look at the sequential order patterns from Q4 to Q1, we saw about $59 million of order uptick. $14 million of that was tied to FSDP; half of that, I'd say, is blanket with our large customers that give us blanket that we ship throughout 2024. The other half is normal book-to-bill. You look at FMT, we're up about $28 million in orders sequentially. Again, half true demand that we've about tied to our bellwether businesses and the other half being blanket. And lastly, FSDP is the story around emerging markets and the growth coming out of India, that's really exciting for us. So you saw that sequentially. So again, I think the key here, the focus is to look at it sequentially because I think that's a better way to look at the business, given where we are in the cycle.

Our next question comes from the line of Nathan Jones with Stifel.

Getting back on the HST order patterns and the sequential improvement that you're seeing there. It's obviously up quite a lot off the bottom from the third quarter of '23. Customers did a lot of inventory destocking out of some of those businesses. Is it your view that customer inventories have been rightsized and we're kind of moving back to an area where your orders are pretty close to what your end customers are selling? Or is that still continued destocking going on from your customers? And do you have visibility into that?

Well, so I'll kind of break down HST because I think the answer varies a bit depending on the portion of the pieces. So half of it is broadly industrial, again, more like FMT and the rest of IDEX. And I think they're—like in those other areas, I'd say the destocking trends are largely past us. And so part of that lift you're seeing in that industrial core. And it's because, frankly, we're at about the levels of consumption, and as those become more positive, we rise with them. So you see the same dynamic in about half of HST that you see elsewhere. I think in the other areas, it's a little trickier and the visibility, to be fair, is a little bit murkier because of just the extension of those supply chains. So now in life science and analytical instrumentation, of course, we can best see inventory between us and factories. And ultimately, that cleared very fast for us, so I don't see an inventory accumulation there. End devices, which, of course, have global reach, are harder for us to see. We ask about it all the time, and there probably are pockets here and there of different platforms and things that are out there that we're probably still working through. So I'd say there may be some moderate or minor effect there, but they're just harder to see and they're kind of outside the four walls of where our usual experience is. And then in semicon, I think it varies as well because there's such discrete and different pieces of semicon. So things associated with memory, as I said, for us, that's kind of simple consignment stock and it's starting to move off the bottom, which would indicate, okay, we cleared that inventory too. Some of the higher-tech things at the other end of the spectrum, more anchored towards high-end lithography or metrology. I think—and quite honestly, we're just waiting—the entire industry is waiting for a stronger demand catalyst there to get it moving. So figure half of the segment generally clear, looks a lot like industrial IDEX, and then I'd say kind of 50-50 in the other half, depending on these two large pieces.

That's helpful. Maybe back on the margin question and where it gets back to in a more normalized volume environment, I think you said 30%. Is that—first, is that an EBITDA margin target? Because historically, we've been talking about operating margins...

EBITDA margins item.

Yes. And I would think that during this downturn, that this business carries a lot of very highly-skilled labor that you would be really hesitant to rationalize during your downturn, particularly one that's likely to be short and cyclical. And so that's led to some of these pretty high decrementals that you're seeing in that segment. But should all that result in very good operating leverage and very high incrementals as we come out of the other side. Is there any commentary you can give us on kind of what you'd expect to see out of incremental margins in HST as we see that volume adjust?

Well, Nathan, I think the point you made is the answer, but I will say it, which is, to your point, we've been very, very thoughtful in terms of how we rightsize the business. Again, as Eric talks about the long-term vision, we believe in the long vision of this business and expect this business to grow as we come out of the cycle. So as you think about the incrementals on the uptick, I'd say it's 35% to 40% is the incrementals you should expect, if not north of it, depending on the investments we make in the business over the long term as we grow the business.

Our next question comes from the line of Joe Giordano with TD Cowen.

Just curious like on the tools and the life science piece of HST, is there like—medium term, is there any sort of adjustments at the top end of like what this potential is? I mean I know we're going to get to the end of the destock and all that over the next bit here and long term there's a clear call. But like do we need to like adjust what we think like the potential is over like a multiyear period here given what's happening internationally and things like that?

Well, I think there's probably a couple of things out there to consider at the highest level when you're projecting. I think you hit one of them. So the ultimate position of China in this market, I think is something everybody has to think about. It's a big part of the issue currently because it was such a high catalyst of growth here more recently for most of the customers that we supply. And so kind of where that comes out there, as you know, there are some regulatory things that are out there in the mix. I haven't seen a big move in this particular area from any stimulus programs that have been applied over there. So kind of where it ultimately settles in, I think, is an open question. On the other side, though, probably on the positive and the question of does it offset it, we continue to see just massive technology advancements here. I know the things that we're working on with customers in our building certainly have even potentially higher growth potential as you think of where that may land on a global population and what work that could get done. So kind of I put the nature of innovation as a positive and where it goes and keeping track of it and seeing what it can all do right next to a question on China is probably the two biggest calls.

Would you say like globally, it's longer-term fungible? Like there's a baseline global demand that is going up and whether it's China or elsewhere, where this needs to be put in, it needs to be put in, and like it's just friction over like a shorter-term basis? Is that how you kind of think about it?

I think that's exactly how we would think about it. I mean, it's—the China piece, in particular, is pronounced from just the relative nature of what it had been and what it is now. And that's not trivial. That's couple of positive years on the one side and a few of adjustment on the other. But long term, this is ultimately about applying life-saving technology, transformational technology, of course, to a global population. And I think certainly, one of the things that we always intended with our franchise is having global reach and scale. We have that. So if it begins to shift around and move from one region to another to do the work, that's actually something we're very well set up to align with. So I think that's well stated. It's—in the near term, it's—which way are the winds blowing. I think more medium term, it's more regionally around some of these key questions. And long term, it seems very, very assured. And I think it's ultimately about do you have the scale to go chase it, and we do.

Our next question comes from the line of Matt Summerville with D.A. Davidson.

I wanted maybe just a little bit of commentary and maybe a little bit more granularity on what you're seeing in the M&A pipeline at present, which businesses, which end markets are you focused on? Have you seen as far as purchase price multiples? Just a little more detailed color there.

Yes. Well, I think you saw in the remarks that I had. I mean, I made a special point to talk about the fact that we're looking for complementary pieces. So things that attach well to other areas of IDEX and I mentioned, at high level, how we had done that over the last 3 years in the optics space, the water space. And then I call it kind of material-intensive processing on small form factor, that's where Muon fits and frankly, STC. So these are businesses that when we purchase them, not only are we purchasing a great IDEX-like business, but we can see attachment points, more natural synergies. And frankly, it matches a vision of something that we're trying to create there, much of which comes back to the question that we just talked about in the life sciences arena of can we have the relative and the absolute scale to do that job well as it globalizes. And so I think the areas that I highlighted here would be—you can take those as areas of high interest, and you can see the evidence of things that we've applied there. The valuations, I think we've consistently said for the kind of quality that we look for at IDEX, it remains quite pricey. I will tell you, I think we've put a lot of work here recently where the capital deployed number for us would be higher if we were willing to go a couple of more turns and meet some of the expectations, and we just did not. We still are very, very disciplined about what we can do with the business. Even in the case where it's complementary like that, they're just—we know what the limit is. And we've held that line and will continue to do that. So I think one other aspect that I would put is a net positive for us. We continue to find ourselves in proprietary spaces, having conversations with people generally where it's only the two of us. And so that's—I think that's important in this environment, too. That gives you a bit of a head start. But the takeaway here is absolutely urgent. I mean we're putting the time in, we're putting the effort in. We are narrower in our focus because we are looking for things that attach well and scale quite naturally within these niches, but—and we're doing it on a proprietary basis, but we are super careful about where the line needs to end on valuation for us.

Got it. And then just as a follow-up, could you maybe spend a minute talking about kind of the ultimate duration and strength of the muni water and wastewater cycles as you kind of see it playing out for IDEX?

Yes. I think, as I've said a couple of times before, I don't think it launches with a lightning bolt or a bang, but actually, the duration of it is going to be very durable. You've had a lot of intentional funding announcements put out there. Those always take a while to find their way home and funded projects that have been engineered and are now being deployed. So I think what's very positive about this cycle is the—and I can't think of another one where I've seen this much intentional focus, and frankly, this much unfortunate reinforcement in terms of things in systems that are just not able to cope with the current climate that we have out there. So you put those two things together, and what we know is that level of confidence is what it really takes for engineers and municipalities and industrial spaces to do the work, to make it through the budget cycles, the inevitable number of conversations to get things approved to get them in front of us. The last point I always remind external folks to consider when they think of our water businesses, a lot of what we're doing is analysis. So we're doing infrastructure analysis and then providing that over generally for a technical part of our customer set. And so in that way, we're actually well-positioned to kind of—as a diagnostic at the beginning of the cycle because much of the time, they're using our information and our output to substantiate larger capital projects. And so kind of here in the beginning of a multiyear cycle is a good place for IDEX to be because we're actually helping them put the projects together that are going to extend the cycle overall.

Our next question comes from the line of Rob Wertheimer with Melius Research.

Eric, you touched on an interesting topic in your opening comments just on semiconductors and the AI shift, which is obviously driving huge—in demand, pricing power, all sorts of things across pockets of industrials. I wonder, do you have any expanded remarks on what your exposure is there, how your technological capabilities are changing, whether you're entering kind of a new segment of semiconductors? Anything you can flesh out there if you're willing.

Yes. No, I appreciate it. I mean it's still a modest portion of IDEX, overall, but it's growing, and it's growing and has found its way into the portfolios of some of the things we've recently acquired in HST. So we're certainly more interested and focused on it. And as we've brought those technologies in, I mean, we thought about this revolution and the jobs to do within it, particularly the hardest ones is our #1 area of interest. So we're often going right into lithography instruments and some of the most advanced that are out there because those are the ones that are being called upon to do the work, to create the chip architecture that's going to support the hardest piece of this. So we're well-indexed there. We've long had a metrology portion of our business that's all about validating that, that job was done well. Even on the piece within water that we have that’s somewhat semi-focused, I mean it's absolute critical water purification, delivery, and heating. And we talked about that in our sustainability report as one of the best eco-friendly solutions we have in the whole company. And so it's a broad market. It's fragmented and segmented into different uses and technologies. But you can think of us as generally thinking about what are the hardest jobs to do that provide the most critical differentiation when they are done, because typically for us, that's where the most economic benefit comes from. And so we're tracking a lot of those different trends, the size of chips, the way that they're being packaged, and looking for all the ways that we can play there. So just think of that as that's how we're indexed, that's increasing. And so ultimately, as that plays out, I think we're very, very well positioned.

There are no further questions in the queue. I'd like to hand the call back to management for closing remarks.

Well, thank you very much. Thanks for everybody joining today. We appreciate your interest in IDEX. And look, I think, no doubt, there's some uncertainties out there in the near term, whether it's inflation, interest rates, geopolitical tensions—it's obviously an election year. We hear a lot of chatter about that out in the background. As I said, I think there's some sensitivity to it. But more broadly, I still think the arrows are very positive for businesses like ours and others over time. As we're tracking all that, we think it's helpful to provide that color to you as we do it. And as you know, we were very good at moving resources around from here to there within this high-quality portfolio to continue to execute for shareholders and customers. But I really step back and say, I think we're incredibly positioned for where things are going in the long term. We've had that discussion here with life science and analytical instrumentation, how powerful that's going to be over time. We just had it here more recently with our discussion around semicon and the revolutionary aspects of AI and the part we play there. And then we could go through a host of other applications, more of the niche than not, and take you through that as well. And that's what we're building each and every day through our own organic efforts and the efforts of the company. And so we're laser-focused on the things that matter, both short-term and long-term, and look forward to continuing to talk with you along the way and the quarters to come. Have a great day.

Thank you.

Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.